Supplementary Figure S1

Slides:

Advertisements

Similar presentations

IMMUNOPHENOTYPING OF HEMATOPOIETIC PROGENITOR CELLS BY MULTIPARAMETER FLOW CYTOMETRY.

Advertisements

Supp. Figure 1. The pattern of T cell infiltration and vessel and cancer cell destruction is consistent throughout tumor regions. A. Immunohistochemistry.

Figure S1 a. Neutrophilsb. Non-inflammatory monocytes c. Macrophages or DCs d. Inflammatory monocytes SSC FSC B C SSC * * * * * III Count F4/80 A.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

FSCCD40 mediumFluCL %82 %97 % SSC FSC GEN2.2 cells B mediumFluCL097CpG ACpG B GEN2.2 GENshTLR7 % CD40 positive cells TLR7TLR9 0.0.

Supplementary Figure.1 NF- κ B p65 / β- actin protein ** ID8HM ** * * * β-actin ID8 HM-1 +CPA(0.7uM)non-treat+CPA(7uM)+CPA(70uM) NF-κB p65 β-actin.

(A) (B) Supplementary Figure S1. FSC-A Live/Dead CD3 NK1.1 CD4 CD8 4-1BB PD-1 4-1BB PD-1 CD4+CD8+CD3+Live cells (A) Isotype-treated FSC-A Live/Dead CD3.

CD44 PD-L1 FSC Human/Mouse Stromal Markers FSC DAPI FSC SSC FSC-W FSC-H SSC-W SSC-H Live cells Tumor cells CD44 - CD44 + Supplementary Figure S1. Gating.

AB C D E F G H Supplemental Fig. 1. Figure S1. MIF induces maturation of CD11b + but not CD8α + DCs in spleen from Mif -/- mice infected with T. gondii.

Supplemental Figure 1. Loss of Stat3 expression did not change IFN-induced chemokine levels in tumors. (A) Realtime PCR analysis of mRNA expression levels.

Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

B16 4T1 CT26 FL 72kD Cleaved 45kD (a) (b) Supplemenatry fig. 1 Full length (FL) and cleaved DR6 expression in B16, 4T1 and CT26 cells.

Supplementary Figure S1 a

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

Figure 2. Proposed phenotypes of type 2 DCs

Supplementary Figure 1 CD45 CD14 FSC CD123 HLA-DR CD11c Lineage

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

“Analyses of Pre-therapy Peripheral Immunoscore and Response to

Supplementary Table 1: Antibodies used in this study

A B C Supplementary Figure 1 Group 1 Group 2 Group 3 #1 #2 #3 #4 #5 #6

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma Sun Hye Kim, Man Li, Sebastian.

Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Supplementary Figure S1

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Volume 74, Issue 6, Pages (December 2018)

Figure S2 Gating strategy of AT2 cells based on EpCAM and MHCII

Volume 6, Issue 6, Pages (March 2014)

Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.

Figure 1 The role of CTLA4 and PD1 in T cell activation

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

B A D C * * E F Panc-1 cells Figure S1 DNA ladder h

Supplementary Figure 1 FSC-A SSC-A HC UC CD

Volume 26, Issue 3, Pages (March 2007)

Figure S1 Figure S2.

Relative protein levels

a b Supplementary Figure 1

Supplementary Figure 1. A

Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4 depends on strength of α-CD3/28 signaling. Role of IL-27 in expression of PD-L1, LAG-3, and CTLA-4.

Refer to word document for this table

Immune cell populations, activation, and NKG2D and H60a expression in the spleen of untreated and antibiotic-treated Klrk1+/+ and Klrk1−/− NOD mice. Immune.

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Supplementary Figure S4

Deciphering and Reversing Tumor Immune Suppression

Volume 25, Issue 1, Pages (January 2017)

A B Supplementary Figure S1 PC3 cells Vehicle 3β-Adiol

Cell-mediated immunity Regulation of the immune response

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Volume 12, Issue 2, Pages (July 2015)

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

IL-27 induces expression of multiple IR by CD8+ T cells.

Dendritic-Cell-Based Therapeutic Cancer Vaccines

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

ODM-203 administration results in immune activation in a syngenic model. ODM-203 administration results in immune activation in a syngenic model. Effect.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT signaling. HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT.

Complete Vehicle Systems.

Supplementary Figure S1

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Fig. 7 Differences in the tumor microenvironment between transplant and transgenic BRAFV600E-driven melanoma models may underlie refractoriness of iBIP2.

Supplementary Table 2. Antibodies and conditions used for the IHC studies.

Supplementary Figures

Presentation transcript:

Supplementary Figure S1 FSC SSC FSC-A FSC-H Live/Dead CD3 F4/80 CD11b Ly6G Ly6C b) FSC SSC Live/Dead CD45 CD11b CD3

Supplementary Figure S2 FSC SSC Live/Dead CD8 CD4 Granzyme-B CD62L CD44 PD-1 Lag3 b) Frequency Exhausted CD8 T-cells p = 0.01 Lag3 (mRNA) Cd3d Cd3g c)

Supplementary Figure S3 PD-1 PDL-1 CTLA-4 Bulk Tumor b) CD8+ T cells c) CD4+ T cells d) GMDSCs

Supplementary Figure S4 Panc02 b) Neu-N c) Neu-N

Supplementary Figure S5 b) Neu-N c) d) Neu-N Panc02

Supplementary Figure S6 G-MDSCs M-MDSCs a) b) Neu-N c) G-MDSCs d) M-MDSCs Panc02 e) f)

Supplementary Figure S7 Pathways Downregulated b) Pathways Upregulated c)

Supplementary Figure S8 Comparison ENT vs. ENT + a-CTLA-4 ENT vs. ENT + a-PD-1 Vehicle vs. ENT Vehicle vs. ENT + a-CTLA-4 Vehicle vs. ENT + a-PD-1

Supplementary Figure S9 ENT + a-PD-1 + a-CTLA-4 a) Ladder Vehicle ENT ENT + a-PD-1 ENT + a-CTLA-4 Splenic GMDSCs 80 kDa STAT3 50 kDa b-actin 80 kDa pSTAT3 50 kDa b-actin b) c) d) e)

Supplementary Figure S10 b) Neu-N c) Panc02

Supplementary Figure S11 b) Neu-N Panc02 c) d) Neu-N Panc02 e) f) Neu-N Panc02 g) h) Panc02 Neu-N